Clinical study for the treatment of Dravet Syndrome available at Rare Disease Research

Rare Disease Research is conducting a clinical study investigating the efficacy of orally administered Lorcaserin as adjunctive treatment in subjects with Dravet Syndrome. The study will assess the percent change in frequency of convulsive seizures when compared to placebo.   
Contact us if you are interested in learning more about this study and if you meet the following requirements: 

  • Male or Female, 2 years of age or older 
  • Confirmed diagnosis of epilepsy with Dravet syndrome 
  • Have had at least 4 convulsive seizures during the 4 weeks of screening for the study 
  • Currently taking at least 1 antiepileptic drug on a stable dose for at least 4 weeks before study screening
  • Have NOT used lorcaserin within 4 weeks before screening for the study

You can contact us directly for additional study specific information.

Contact us

You can also contact us directly at: 
678 - 883 - 6897